Researchers use AI to turn existing antibodies into cell penetrating tools for neurodegenerative research

Years of laboratory research could soon be bypassed thanks to a new breakthrough from the University of Essex that allows scientists to rapidly repurpose existing antibodies rather than building treatments from scratch. By using artificial intelligence to redesign how these molecules behave, the team has created a shortcut that could drastically accelerate the development of therapies for Parkinson's, Alzheimer's, and motor neurone disease. Natural antibodies normally work outside cells to fight off infections, and placing them inside a cell causes them to clump together and fail. Led by Dr Caitlin O’Shea and Dr Gareth Wright, the researchers discovered that the issue comes down to surface electrical charge. Using specialised design software, they altered the charge of standard antibodies so they remain stable and functional inside living cells. These microscopic tools, called intrabodies, can be manufactured directly within cells to seek out and attach to troublesome proteins before they cause damage. In findings published in Nature Communications, the team successfully converted 672 different antibodies into stable intrabodies, making the entire collection freely available to the global scientific community. Because many neurological conditions take root when proteins misbehave deep inside brain cells, having tools that operate directly in that environment is vital. By giving decades of existing antibody research a powerful second life, this approach offers an immediate leap forward for laboratory studies and future targeted therapies.